Mitoxantrone Injection 2 mg (Mitoxantrone (Mitoxantrone Hydrochloride) SOLUTION) 2 MG

Mitoxantrone Injection 2 mg is a chemotherapy medication used to treat certain types of cancer. This intravenous solution is manufactured by Fresenius Kabi Canada Ltd. and is available in a 10 mL pack size.

Strength

2 MG

Pack Size

10ML

Manufacturer / TM Owner

FRESENIUS KABI CANADA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mitoxantrone Injection is primarily used in cancer treatment, specifically for conditions like advanced prostate cancer and certain types of leukemia. It works by interfering with the growth of cancer cells, helping to slow or stop their proliferation. Patients often wonder, 'What is Mitoxantrone used for?' and the answer lies in its role as an antineoplastic agent, targeting rapidly dividing cells.

Side Effects

Common effects of Mitoxantrone Injection may include nausea, vomiting, and fatigue. Some patients may experience hair loss or changes in blood cell counts. These effects can vary widely among individuals and are typically managed under medical supervision.

Precautions & Warnings

Mitoxantrone Injection should be handled with care, as it is a potent medication. It is important to follow all safety guidelines provided by healthcare professionals. Patients should be monitored regularly for any adverse reactions, and the medication should be stored as directed to maintain its efficacy.

Avoid Interactions

Mitoxantrone may interact with other medications, including those that affect the immune system or blood cell production. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also affect the body's response to Mitoxantrone.

References

Frequently Asked Questions

Mitoxantrone Injection is used in the treatment of certain types of cancer, including advanced prostate cancer and some leukemias.

Mitoxantrone Injection is administered intravenously, typically by a healthcare professional in a clinical setting.

Common side effects may include nausea, vomiting, fatigue, and hair loss. Regular monitoring is recommended.

Mitoxantrone may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Mitoxantrone Injection should be stored according to the manufacturer's guidelines to maintain its effectiveness.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.